Galectin Therapeutics Inc. announced that its Investigational New Drug (IND) application for belapectin in combination with a checkpoint inhibitor for the treatment of Head and Neck cancer has been filed with the U.S. Food and Drug Administration (FDA) Oncology division. Galectin Therapeutics also received a Study May Proceed letter for a Phase 2 clinical trial entitled A Phase 2 Study of the Efficacy and Safety of Belapectin in Combination with Pembrolizumab (Keytruda®) as First-Line Treatment in subjects with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.91 USD | -3.96% | -16.43% | +74.70% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+74.70% | 188M | |
+22.82% | 44.96B | |
+1.09% | 42.65B | |
+45.89% | 41.85B | |
-4.27% | 29.04B | |
+11.14% | 26.08B | |
-21.29% | 19.03B | |
+6.51% | 12.75B | |
+28.65% | 12.06B | |
-3.98% | 11.75B |
- Stock Market
- Equities
- GALT Stock
- News Galectin Therapeutics Inc.
- Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer